These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33067480)

  • 1. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
    Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
    Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
    Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
    Front Immunol; 2021; 12():557994. PubMed ID: 34220791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
    Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
    Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival.
    Zhang J; Caruso FP; Sa JK; Justesen S; Nam DH; Sims P; Ceccarelli M; Lasorella A; Iavarone A
    Commun Biol; 2019; 2():135. PubMed ID: 31044160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
    Huang R; Lu X; Sun X; Wu H
    Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
    Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
    Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
    Bagley SJ; Hwang WT; Brem S; Linette GP; O'Rourke DM; Desai AS
    J Neurooncol; 2019 Jan; 141(1):95-102. PubMed ID: 30353265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
    González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
    Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of HLA-II related to LAG-3
    Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
    Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.
    Roufas C; Chasiotis D; Makris A; Efstathiades C; Dimopoulos C; Zaravinos A
    Front Oncol; 2018; 8():27. PubMed ID: 29515971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
    Dubinski D; Won SY; Rauch M; Behmanesh B; Ngassam LDC; Baumgarten P; Senft C; Harter PN; Bernstock JD; Freiman TM; Seifert V; Gessler F
    Front Immunol; 2021; 12():627650. PubMed ID: 33868245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
    Liu Y; Song C; Shen F; Zhang J; Song SW
    PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
    Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
    Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.